5061972025-04-012025-06-305061972025-04-012025-06-30in-capmkt:OtherExpenses1Member5061972025-04-012025-06-30in-capmkt:OtherExpenses2Member5061972025-04-012025-06-30in-capmkt:OtherExpenses3Member5061972025-04-012025-06-30in-capmkt:OtherExpenses4Member5061972025-04-012025-06-30in-capmkt:OtherExpenses5Member5061972025-04-012025-06-30in-capmkt:OtherExpenses6Member5061972025-04-012025-06-30in-capmkt:OtherExpenses7Member5061972025-04-012025-06-30in-capmkt:OtherExpenses8Member5061972025-04-012025-06-30in-capmkt:OtherExpenses9Member5061972025-04-012025-06-30in-capmkt:OtherExpenses10Member5061972025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15061972025-04-012025-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares506197BLISSGVSNOTLISTEDINE416D01022BLISS GVS PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312025-07-292025-07-22INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical & Healthcare2025-07-2913:00:002025-07-2916:30:00Not applicable2025-04-012025-06-30UnauditedConsolidated20746920003545400002429232000934123000205747000-220955000310026000547150008201300043245400017981230006311090000631109000204949000-174530001874960000443613000000044361300058521000502134000430379000132340004889000001323400010549800014.084.04004.084.040.00050.06210.12531. The above unaudited financial results which are published in accordance with Regulation 33 of the SEBI Listing Obligations & Disclosure Requirements Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on July 29, 2025. These unaudited financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India. <BR> 2. The above unaudited financial results for the quarter ended June 30, 2025 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Kalyaniwalla & Mistry LLP have issued limited review reports with unmodified conclusion on the standalone and consolidated unaudited financial results. <BR> 3.As the Companys business activity falls within a single operating segment viz Pharmaceutical and Healthcare, no segment information is disclosed. <BR> 4. Employee Benefit Expenses includes Share Based Payment expense on account of ESOP Scheme, 2019 of Rs. 140.07 Lakh quarter ended June 30, 2024 Rs.129.40 Lakh as per Ind AS 102 Share based Paymentfor the quarter ended June 30, 2025. <BR> 5. During the quarter ended June 30, 2025, the Company has allotted 1,27,250 equity shares of Rs. 1 each fully paid, on exercise of stock options by employees in accordance with the Company's ESOP Scheme, 2019. The outstanding number of options as at June 30, 2025 are 17,16,250. <BR> 6. The Board of Directors in its meeting held on May 12, 2025 has approved the sale of 51 percent stake in its step-down subsidiary, Greenlife Bliss Healthcare Ltd, Nigeria, held by its subsidiary, Bliss GVS International Pte Ltd, Singapore, to non-controlling shareholder for a total consideration of USD 13,00,000 subject to necessary regulatory and other approvals. Since the Company has lost control on Greenlife Bliss Healthcare Ltd. w.e.f April 01, 2025, the said Company has not been considered for consolidation. <BR> 7. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the previous financial year, which were subject to limited review.Freight outward71840000ECL expenses62993000Travelling and Conveyance expenses13588000Repairs and Maintenance43466000Power and Fuel28018000Business Development expenses117799000Corporate Social Responsibility expenses17257000Sales Promotion expenses15641000Legal and Professional Charges20481000Others41371000Remeasurement of the defined benefit liabilities/ (asset)-1273000-1273000-320000Exchange differences in translating the Financial Statements of Foreign Operations79477000794770002000300058521000